BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30804731)

  • 1. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy.
    Kim WS; Kim HS; Shin J; Park JC; Yoo HW; Takenaka T; Tei C
    J Korean Med Sci; 2019 Feb; 34(7):e63. PubMed ID: 30804731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
    Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
    PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey.
    Barman HA; Özcan S; Atıcı A; Özgökçe C; Öztürk A; Kafalı AE; Çakar NE; Tavşanlı ME; Küçük M; Şahin I; Okuyan E
    Anatol J Cardiol; 2020 Jan; 23(2):79-85. PubMed ID: 32011328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy.
    Terryn W; Deschoenmakere G; De Keyser J; Meersseman W; Van Biesen W; Wuyts B; Hemelsoet D; Pascale H; De Backer J; De Paepe A; Poppe B; Vanholder R
    Int J Cardiol; 2013 Sep; 167(6):2555-60. PubMed ID: 22805550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis).
    Güzel T; Çağlar FNT; Ekici B; Kış M; Öztaş S; Öz A; Gök G; Kolak Z; Akşit E; Sarıca SA; Bayrak M; Birdal O; Uğuz B; Gitmez M; Berk Gİ; Oğuz M; Çalık AN; Kılıç S; Zoghi M; Ergene AO
    Int J Cardiovasc Imaging; 2023 Jun; 39(6):1143-1155. PubMed ID: 36920623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.
    Kubo T; Ochi Y; Baba Y; Hirota T; Tanioka K; Yamasaki N; Yoshimitsu M; Higuchi K; Takenaka T; Nakajima K; Togawa T; Tsukimura T; Sano S; Tei C; Sakuraba H; Kitaoka H
    J Cardiol; 2017 Jan; 69(1):302-307. PubMed ID: 27554049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective investigation to establish new screening approach for the detection of patients at high risk of Fabry disease in male left ventricular hypertrophy patients.
    Kubo T; Amano M; Takashio S; Okumura T; Yamamoto S; Nabeta T; Oikawa M; Kurisu S; Ochi Y; Sugiura K; Baba Y; Kuroiwa H; Hirota T; Yamasaki N; Ishii S; Nochioka K; Takeishi Y; Yasuda S; Tsujita K; Izumi C; Kitaoka H
    J Cardiol; 2022 Oct; 80(4):325-331. PubMed ID: 35643740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
    Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
    Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS).
    Palecek T; Honzikova J; Poupetova H; Vlaskova H; Kuchynka P; Golan L; Magage S; Linhart A
    J Inherit Metab Dis; 2014 May; 37(3):455-60. PubMed ID: 24173410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation.
    Baptista A; Magalhães P; Leão S; Carvalho S; Mateus P; Moreira I
    Arq Bras Cardiol; 2015 Aug; 105(2):139-44. PubMed ID: 26269958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for Fabry disease in patients with left ventricular hypertrophy.
    Mawatari K; Yasukawa H; Oba T; Nagata T; Togawa T; Tsukimura T; Kyogoku S; Ohshima H; Minami T; Sugi Y; Sakuraba H; Imaizumi T
    Int J Cardiol; 2013 Aug; 167(3):1059-61. PubMed ID: 23168011
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
    Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
    Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR).
    Kis M; Dogan Y; Yildirim A; Güzel T; Bekar L; Akhan O; Dogdus M; Harbalıoğlu H; Karabulut D; Soydan E; Zoghi M; Ergene O;
    Acta Cardiol; 2022 Nov; 77(9):836-845. PubMed ID: 36222672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of screening for Fabry disease among male dialysis patients.
    Ichinose M; Nakayama M; Ohashi T; Utsunomiya Y; Kobayashi M; Eto Y
    Clin Exp Nephrol; 2005 Sep; 9(3):228-32. PubMed ID: 16189631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
    Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
    Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.
    Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM
    J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.
    Sachdev B; Takenaka T; Teraguchi H; Tei C; Lee P; McKenna WJ; Elliott PM
    Circulation; 2002 Mar; 105(12):1407-11. PubMed ID: 11914245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
    Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.
    Oikawa M; Sakamoto N; Kobayashi A; Suzuki S; Yoshihisa A; Yamaki T; Nakazato K; Suzuki H; Saitoh S; Kiko Y; Nakano H; Hayashi T; Kimura A; Takeishi Y
    BMC Cardiovasc Disord; 2016 May; 16():83. PubMed ID: 27160240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.